Frequency of CD5-expression and its association with trisomy 3 and 7 in diffuse large B-cell lymphoma. A tissue-microarray analysis of 306 cases

Zimpfer, Annette; Pehrs, Ann Christine; Tzankov, Alexandar; Went, Philip; Maurer, Robert; Pileri, Stefano; Dirnhofer, S.

doi:10.1016/s0344-0338(04)80528-4

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its finding in 109 de novo cases was supposed to represent a unique subgroup of DLBCL because of the uniform phenotype (CD5 + /CD10 − /CD19 + /CD20 + /CD21 + /CD23 − /cyclin D1 − ), usual centroblastic morphology and aggressive clinical behavior (Yamaguchi et al 2002; Suguro et al 2006). However, the putative adverse prognostic relevance of CD5 expression has not been confirmed by other studies, which instead correlated CD5 positivity to the occurrence of other specific molecular aberrations (Katzenberger et al 2002; Karnan et al 2004; Zimpfer et al 2004; Yoshioka et al 2005). …”

Section: Prognostic Significance Of Immunophenotypic Cellular Differementioning

confidence: 90%

Prognostic Significance ofin situPhenotypic Marker Expression in Diffuse Large B-cell Lymphomas

2007

View full text Add to dashboard Cite

Diffuse large B-cell lymphomas (DLBCL) are the most common lymphoid malignancies, and encompass all malignant lymphomas characterized by large neoplastic cells and B-cell derivation. In the last decade, DLBCL has been subjected to intense clinical, phenotypic and molecular studies, and were found to represent a heterogeneous group of tumors. These studies suggested new disease subtypes and variants with distinct clinical characteristics, morphologies, immunophenotypes, genotypes or gene expression profi les, associated with distinct prognoses or unique sensitivities to particular therapy regimens. Unfortunately, the reliability and reproducibility of the molecular results remains unclear due to contradictory reports in the literature resulting from small sample sizes, referral and selection biases, and variable methodologies and cut-off levels used to determine positivity. Here, we review phenotypic studies on the prognostic signifi cance of protein expression profi les in DLBCL and reconsider our own retrospective data on 301 primary DLBCL cases obtained on a previously validated tissue microarray in light of powerful statistical methods of determining optimal cut-off values of phenotypic factors for prediction of outcome.

show abstract

Section: Prognostic Significance Of Immunophenotypic Cellular Differementioning

confidence: 90%

Prognostic Significance ofin situPhenotypic Marker Expression in Diffuse Large B-cell Lymphomas

2007

View full text Add to dashboard Cite

show abstract

Frequency of CD5-expression and its association with trisomy 3 and 7 in diffuse large B-cell lymphoma. A tissue-microarray analysis of 306 cases

Cited by 1 publication

References 0 publications

Prognostic Significance ofin situPhenotypic Marker Expression in Diffuse Large B-cell Lymphomas

Prognostic Significance ofin situPhenotypic Marker Expression in Diffuse Large B-cell Lymphomas

Contact Info

Product

Resources

About